Most state Medicaid programs do not cover weight loss drugs. As of early 2023, only about 1 in 5 state Medicaid programs covered any anti-obesity medication, and just 11% offered unrestricted coverage of at least one weight loss drug. Federal law specifically allows states to exclude these medications, and the high cost of newer GLP-1 drugs has made many states even more reluctant to add them.
Why Most States Can Legally Exclude Coverage
The Social Security Act, which governs how Medicaid drug benefits work, includes a provision that lets states exclude “agents when used for anorexia, weight loss, or weight gain” from their formularies. This is one of a handful of drug categories that states are explicitly permitted to deny, no matter how medically necessary a doctor considers the prescription. Unlike most other FDA-approved medications, weight loss drugs sit in a unique legal gray zone where coverage is entirely optional.
This means your access to weight loss medication through Medicaid depends almost entirely on which state you live in. There is no federal requirement for states to cover these drugs, and most choose not to.
The Cost Problem Driving State Decisions
Medicaid spending on GLP-1 medications (the drug class that includes popular weight loss and diabetes drugs) has exploded in recent years. Gross spending on selected diabetes and weight loss GLP-1 drugs reached $9.4 billion in 2023, a 540% increase from 2019. By 2024, the average Medicaid cost per GLP-1 prescription hit $1,000, and these drugs accounted for over 8% of all Medicaid prescription spending before rebates, up from just 1% in 2019.
That spending pressure is already forcing states to reverse course. North Carolina, which had been covering GLP-1 weight management drugs, announced it would discontinue that coverage effective October 1, 2025, citing shortfalls in state funding. Wegovy, Zepbound, and Saxenda were all removed from the state’s preferred drug list for weight management purposes. North Carolina’s Medicaid agency explicitly acknowledged the potential of these drugs but said funding simply wasn’t available to continue.
The Diabetes Loophole
Here’s where it gets complicated. Several of the most popular weight loss drugs share active ingredients with diabetes medications. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Tirzepatide is sold as Mounjaro for diabetes and as Zepbound for weight loss. Medicaid programs that refuse to cover the weight management versions typically do cover the diabetes versions, because diabetes drugs don’t fall under the optional exclusion.
This creates a situation where the same molecule may be covered or denied based on the diagnosis code your doctor submits. If you have type 2 diabetes, your GLP-1 prescription is far more likely to be approved. If your primary diagnosis is obesity without diabetes, many states will deny the claim. The total number of Medicaid GLP-1 prescriptions grew from about 1 million in 2019 to over 8 million in 2024, but much of that growth reflects diabetes prescriptions rather than weight management.
What Coverage Looks Like in States That Do Cover Them
Even in the roughly 10 states that cover anti-obesity medications, access is rarely straightforward. Most require prior authorization, meaning your doctor must submit paperwork justifying the prescription before it’s approved. The criteria can be strict.
Michigan’s Medicaid program offers a useful example of what these requirements look like in practice. To qualify for a GLP-1 weight loss drug, you must be classified as morbidly obese (generally a BMI of 40 or higher, or 35 with serious health conditions). You also need documented failure of all other clinically appropriate weight loss interventions, including trying and failing preferred, lower-cost anti-obesity drugs first. And coverage is only considered as a measure to avoid the need for bariatric surgery. Some states also require participation in a lifestyle modification program that includes dietary changes and increased physical activity, consistent with FDA labeling that recommends these drugs be used alongside lifestyle changes.
If your state does offer coverage, expect a process that takes weeks and may involve appeals. “Unrestricted” coverage, where a doctor can simply write a prescription without jumping through hoops, existed in only about 5 states as of early 2023.
Bariatric Surgery Is Far More Widely Covered
In a notable contrast, 45 state Medicaid programs cover bariatric surgery with various restrictions. Only two states explicitly exclude it. This creates an unusual situation: the more invasive, more expensive surgical option is almost universally available through Medicaid, while less invasive pharmaceutical treatments are mostly excluded. Nutritional counseling and drug therapy have historically been the least frequently covered obesity treatments in Medicaid, with 33 states making no mention of weight loss drugs in their provider manuals at all.
If you’re on Medicaid and considering your options, bariatric surgery is far more likely to be an available path, though it comes with its own eligibility requirements and waiting periods.
Potential Federal Changes
The Biden administration proposed requiring Medicare and Medicaid to cover obesity medications starting in 2026, which would have eliminated the state-level discretion that currently allows exclusions. The proposal would have also lowered the BMI threshold from 30 to 27 for patients with weight-related conditions. However, this proposal has not been enacted into law, and any future changes depend on congressional action.
Under current law, Medicaid covers anti-obesity medication only for beneficiaries with a BMI of 30 or more who also have diabetes or other weight-related conditions, and even then, only in states that choose to provide coverage. Proposals like the Treat and Reduce Obesity Act have circulated in Congress for years without passing. Until federal law changes, coverage remains a state-by-state patchwork.
How to Check Your State’s Coverage
Your best starting point is your state’s Medicaid preferred drug list, which is typically posted on your state Medicaid agency’s website. Search for the specific drug you’re interested in (Wegovy, Zepbound, Saxenda, or others) and look for whether it appears on the formulary and what restrictions apply. If you’re enrolled in a Medicaid managed care plan rather than traditional fee-for-service Medicaid, your plan may have its own formulary that differs from the state’s, so check with your plan directly.
If your state doesn’t cover weight loss drugs, ask your doctor whether you qualify for any manufacturer patient assistance programs or whether your weight-related conditions (sleep apnea, type 2 diabetes, cardiovascular disease) might make you eligible for the same medication under a different covered diagnosis.